FL-DM1

FL-DM1 is a protein-drug conjugate (PDC) composed of a recombinant human FLT3 ligand (rhFL) conjugated to the cytotoxic microtubule inhibitor emtansine (DM1) via a succinimidyl 3-(2-pyridyldithio)propionate (SPDP) linker. Developed for the treatment of acute myeloid leukemia (AML), FL-DM1 specifically targets the FMS-like tyrosine kinase 3 (FLT3) receptor, which is expressed on the surface of over 90% of AML blasts. Upon binding, the conjugate is internalized into the cell, where the DM1 payload is released to depolymerize microtubules, leading to G2/M phase cell cycle arrest and apoptosis. This targeted approach aims to overcome the limitations of small-molecule FLT3 inhibitors, such as secondary resistance mutations, by utilizing the ligand's natural affinity to deliver a potent cytotoxic payload directly to malignant cells.

Other names

FLT3 ligand-emtansine drug conjugateFLT-3 ligand-emtansine drug conjugateFLT 3 ligand-emtansine drug conjugaterhFL-DM1rhFL-DM-1rhFL-DM 1